Valentina Reshkova, Desislava Kalinova and Rasho Rashkov
Lambert-Eaton myastenic syndrome (LEMS) is an autoimmune disease, affecting the resynaptic neuronal transmission. It is the results of an autoimmune reaction in which antibodies are formed against presynaptic voltage-gated calcium channels (VGCC) in the neuromuscular junction. Its clinical features include muscle weakness and autonomic symptoms. LEMS can occur sporadically or as a paraneoplastic syndrome, associated with different cancers-breast, colon, prostate, pancreas, lung. Lambert-Eaton myastenic syndrome is a rare paraneoplastic syndrome associated in 50% with small cell lung cancer (SCLC), with prevalence 1% among patients with SCLC. We presented a clinical case of a 45 years old woman with SCLC with slow progression associated with paraneoplastic Lambert-Eaton myastenic syndrome.